Attovia Therapeutics, Inc. ATTO
Set alert
15.12 USD +0.07 +0.47%
As of Nov 3, 12:26 PM ET
15.12 Day range 15.90
12.94 52-week range 28.00
- YTD
- -30.96%
- 1 year
- -30.96%
- Open
- 15.90
- Prev close
- 15.05
- Mkt cap
- 690.25M
- Vol
- 34.74K
- Avg vol
- 428.38K
- EPS
- -2.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.12
- High
- 15.90
- Forward P/E
- -9.30
- Beta
- 0.00
- Short ratio
- 0.54
- Inst. own
- 40.86%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 21.62
- 200-d avg
- 21.62
- 1y target
- 42.20
6M chart
Events in this range
- Aug 31, 2026Rating: Morgan Stanley · — → Overweight
- Aug 31, 2026Rating: RBC Capital · — → Outperform
- Aug 31, 2026Rating: Leerink Partners · — → Outperform
- Aug 31, 2026Rating: LifeSci Capital · — → Outperform
- Aug 31, 2026Rating: Citigroup · — → Buy
- Sep 2, 2026Earnings: -4.88; estimate -0.6459; surprise -655.53%
Signals (3)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 42.20 +179.1% upside
Now 15.12
- Target (low)
- 30.00
- Target (mean)
- 42.20
- Target (high)
- 52.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.50 | -0.50 – -0.50 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Next quarter | -0.52 | -0.52 – -0.52 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Current year | -3.45 | -3.45 – -3.45 | 0.00 | 0.0% | 466.67K | 0.0% | 1 |
| Next year | -2.38 | -2.38 – -2.38 | -3.45 | +31.0% | 0 | -100.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 2026 | Citigroup | Initiated | — | Buy |
| Aug 31, 2026 | LifeSci Capital | Initiated | — | Outperform |
| Aug 31, 2026 | Leerink Partners | Initiated | — | Outperform |
| Aug 31, 2026 | RBC Capital | Initiated | — | Outperform |
| Aug 31, 2026 | Morgan Stanley | Initiated | — | Overweight |